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Abstract
Objectives: An established theory for the pathogenesis of tardive dyskinesia is disturbed dopaminergic receptor sensitivity 
and/or dopaminergic intracellular signaling. We examined associations between genetic variants of neurotransmitter 
receptors and tardive dyskinesia.
Methods: We assessed tardive dyskinesia in Caucasian psychiatric inpatients from Siberia (N = 431) and a long-stay 
population from the Netherlands (N = 168). These patients were genotyped for 43 tag single nucleotide polymorphisms in 
five neurotransmitter receptor genes, and the results for the two populations were compared.
Results: Several significant associations with tardive dyskinesia were identified, but only GRIN2A (rs1345423) was found in 
both patient populations. This lack of agreement was probably due to the small effect size of the associations, the multiple 
testing and the small sample size of the Dutch patient population. After reviewing the literature, we propose that the 
constitutive stimulatory activity of serotonergic type 2 receptors may be relevant.
Conclusions: Inactivity of the serotonergic, type 2C receptor or blockade of these receptors by atypical antipsychotic drugs 
may decrease the vulnerability to develop tardive dyskinesia.
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Introduction
Dyskinesia is a movement disorder characterized by invol-
untary, repetitive, and irregular motions that affect the 
mouth and face and/or the limbs and trunk.1 Tardive dyski-
nesia (TD) is a well-known complication of long-term treat-
ment with dopamine (DA) blocking agents, predominantly 
antipsychotic drugs.2 The prevalence of TD can vary, 
because it depends on the influence of several risk factors 
like, for example, age, type, dose, and duration of antipsy-
chotic drug usage, diagnosis, non-therapeutic risk factors, 
and plasma level related pharmacogenetic risk factors.3 For 
over six decades, antipsychotic drugs have remained the 
mainstay of schizophrenia treatment. Schizophrenia is a het-
erogeneous psychiatric disorder, with a lifetime prevalence 
of about 1%. TD in schizophrenic patients is associated with 
poor outcome and TD patients may suffer from more physi-
cal or psychological problems.3 The pathophysiological 
mechanism of psychotic symptoms in schizophrenia is 
partly explained by an increased effect of dopaminergic 
neurotransmission.4,5 This theory is based on the therapeutic 
effects of antipsychotic drugs, which are all DA receptor 
antagonists.6 The development of TD is also associated with 
dysregulation within the dopaminergic system, and is 
thought to be based on a structural change induced by the 
long-term blockade of DA receptors.7,8 These findings may 
explain why dopaminergic dysregulation in patients with 
schizophrenia is related to psychotic symptoms as well as 
spontaneous dyskinesia, for example, drug-naïve first-epi-
sode patients experience spontaneous dyskinesia more fre-
quently than healthy controls.3
It is thought that TD is primarily related to DA dysregula-
tion. Antipsychotic treatment with both serotonergic 5-HT2A 
(HTR2A) and 5-HT2C (HTR2C) antagonists resulted in a 
lower annual incidence of TD.9,10 This finding led to the 
hypothesis that HTR2A and HTR2C activate gamma-amin-
obutyric acid (GABA)ergic interneurons,11 within the cere-
bral cortex, basal ganglia, and mesencephalic areas, resulting 
in decreased dopaminergic activity. Hence, HTR2A and 
HTR2C antagonism increases DA release.12 Schizophrenia 
has substantial hereditary components and is associated with 
dopaminergic dysfunction; therefore, genes related to the 
dopaminergic neurotransmitter system are attractive candi-
dates for studying its genetic basis.4,13 To a lesser extent, this 
is also true for the pathogenesis of dyskinesia.3,14 Therefore, 
numerous investigations have examined the association 
between genetic variants of DA enzymes and receptors when 
symptoms of dyskinesia are present. However, the results are 
inconsistent and even meta-analyses are not conclusive (see 
discussion).
In this report, we present new data on the association 
between genetic variants of neurotransmitter receptors and 
TD. We compared the results of genotyping for 43 tag single 
nucleotide polymorphisms (SNPs) in five receptors in two 
independent patient populations and related the findings 
with the prevalence of TD. Our results do not differ much 
from those found in relevant meta-analyses, which led us to 
propose that genetically determined variations of DA type 2 
receptors and/or DA type 2 receptor signaling are unlikely to 
affect the sensitivity to TD. We suggest that a mechanism 
other than HTR2-induced augmentation of DA release is 
responsible for explaining the lower incidence of TD after 
treatment with atypical antipsychotics.
Materials and methods
Patients
The work described in this article was carried out in accord-
ance with The Code of Ethics of the World Medical 
Association (Declaration of Helsinki 1975, revised in 
Fortaleza, Brazil, 2013) for experiments involving humans. 
The majority of the patients in this study were retrieved from 
three psychiatric hospitals: Tomsk Clinical Psychiatric 
Hospital, Kemerovo Regional Clinical Psychiatric Hospital, 
and Chita Regional Psychiatric Hospital in Siberia. Written 
informed consent was obtained from each subject after 
obtaining approval of the study protocol from the institu-
tional bioethics committee. None of the participants had a 
compromised capacity/ability to consent; hence, consent 
from the next of kin was not necessary and not recommended 
by the local ethics committee. The inclusion criterion was a 
clinical diagnosis of schizophrenia or schizotypal disorder 
(according to International Classification of Diseases (ICD)-
10: F20 and F21, respectively). Exclusion criteria were as 
follows: non-Caucasian physical appearance (e.g. 
Mongoloid, Buryats, or Khakassians), use of clozapine with 
no TD (clozapine may ameliorate TD), relevant pharmaco-
logical withdrawal symptoms, and organic brain diseases. 
Details on the diagnosis and clinical features for the Russian 
and Dutch populations were previously published.15,16 To 
compare antipsychotic medications, all dosages were con-
verted into chlorpromazine (CPZ) equivalents.17 The 
Abnormal Involuntary Movement Scale (AIMS) was used to 
assess TD.1,18 The AIMS scores were transformed into a 
binary variable (presence or absence of dyskinesia) accord-
ing to the criteria of Schooler and Kane.19 In addition, a 
blood sample was obtained for DNA isolation and genotyp-
ing. All genotyping was performed without knowledge of the 
patient’s clinical status.
DNA analysis
The DNA extraction and Veracode Assay were conducted 
according to standard protocols.15 We selected a subset of 43 
informative SNPs, or tag SNPs, that would accurately repre-
sent the majority of SNPs for five neurotransmitter genes: 
the glutamate receptor, ionotropic, N-methyl D-aspartate 2A 
(GRIN2A) gene, glutamate receptor, ionotropic, N-methyl 
D-aspartate 2B (GRIN2B) gene, DRD3 gene, HTR2C gene, 
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and DRD4 gene. The selection method was previously 
described by Xu and Taylor (freely available at http://
snpinfo.niehs.nih.gov). The following criteria have been 
applied for the selection of the tag SNPs: localization in the 
gene including 1000 bp upstream and downstream (5′ and 3′ 
flanking regions), linkage disequilibrium (LD) thresh-
old = 0.8, minor allele frequency (MAF) ⩾ 0.1, maximal dis-
tance between SNPs for calculation of LD = 250,000 bp, 
Genotype data = “European” (dbSNP). We selected only tag 
SNPs that captured at least 10 SNPs.
Statistical analysis
Different strategies were developed to account for missing 
data and interactions between different SNPs. Classical 
logistic regression and a log-linear regression approach were 
used to analyze the data. The Hardy–Weinberg equilibrium 
(HWE) of genotypic frequencies was checked by the chi-
square test. For the SNPs in the X-chromosomal HTR2C 
gene, deviation from HWE was not calculated. The genotype 
prevalence of all polymorphisms was in agreement with 
HWE in the patient groups except for rs11866328 and 
rs7196095 in the GRIN2A gene and rs963468 and rs9817063 
in the DRD3 gene. All calculations were performed in the R 
statistical environment with the SNPassoc package and basic 
R functions.20 The allele prevalence was first calculated sep-
arately in patients with and without dyskinesia to define the 
percentage of missing genotypes. The HWE test was applied 
with Fisher’s exact test to groups. This showed that one SNP, 
rs12858300, was monomorphic; therefore, it was removed 
from further analysis. To analyze associations between the 
SNPs and the phenotypes, we used logistic regression for 
binary response traits and log-linear regression for continu-
ous traits. The following genetic models were tested:
1. Co-dominant. Both alleles of a SNP influenced the 
phenotype.
2. Dominant. Rare allele homo- and heterozygotes were 
tested against common allele homozygotes.
3. Recessive. Common allele homo- and heterozygotes 
were tested against rare allele homozygotes.
4. Over-dominant. Heterozygotes were tested against 
both homozygote alleles.
5. Log-additive. A trend test for the genotypes, similar 
to the allele model, but comparisons were among 
subjects (N) instead of chromosomes (2N). The test 
and estimates were based on a logistic regression 
model that coded the genotypes as 0, 1, or 2 to reflect 
the number of minor alleles.
The statistical significance of a SNP was established with 
a likelihood-ratio test that compared the effect of a polymor-
phism with the null model (only including the intercept). The 
Akaike information criterion was applied to identify the 
model that best fits the data. The SNP effects were quantified 
using the odds ratio (OR) and 95% confidence intervals 
(CIs). In the result tables, an OR for a log-additive model 
corresponds to an association between a rare allele and the 
presence of dyskinesia. The ORs for other models corre-
spond to associations between the presence of dyskinesia 
and rare allele homo- and heterozygotes (dominant), com-
mon allele homo- or heterozygotes (recessive) or heterozy-
gotes (over-dominant).
Dyskinesia was considered a qualitative trait (yes/no), but 
the degree of dyskinesia expression was analyzed as a quan-
titative trait. To avoid 0 values, 1 was added to the dyskinesia 
expression values, and then they were log2-transformed to 
obtain a log-normal distribution. There were many con-
founding factors in patients with schizophrenia, including 
gender, age, duration of disease, use of anticholinergic medi-
cine, dose of anticholinergic medicine, and total CPZ equiv-
alents on the day of assessment. Only gender and total CPZ 
equivalents were determined to be insignificant. The genetic 
models were adjusted for all the significant confounding 
factors.
The statistical power was estimated based on the preva-
lence of the tested phenotypes in the Siberian sample and 
assumptions of complete penetrance and disease allele prev-
alence of 0.2–0.3. For orofacial dyskinesia, the power esti-
mates to detect associations with p-value <0.05 varied 
between 14%–50% for models assuming OR of 1.5; 44%–
94% for models assuming OR of 2.0; and 78%–99% for 
models assuming OR of 2.5. For limb-truncal dyskinesia, the 
power estimates varied between 10%–31%, 27%–75%, and 
53%–95% for these three OR values, respectively. For either 
type of dyskinesia, the power estimates varied between 
18%–65%, 58%–99%, and 91%–99%. Overall, our study 
was reasonably powered to detect clinically relevant associa-
tions with an OR as little as 2.0.
Comparisons
For comparisons, we used the population described by 
Bakker et al.16 They included a group of 168 Caucasian 
patients (M/F ratio: 96/72) who were representative of a pop-
ulation with the most severe chronic mental illness, requiring 
long-stay care at a psychiatric institution. The DNA of these 
patients was analyzed in parallel with our patients’ samples 
and the results were provided to Bakker and colleagues. 
Genotype and allele frequency comparisons were performed 
using a multilevel random regression method with three 
measurement occasions (baseline and two follow-ups) for 
continuous TD and other movement disorders.
Results
Of the 431 Siberian patients (269 males/162 females) 
included, 401 (95.1%) had schizophrenia. The mean age 
was 41.5 ± 15.3 years and the average duration of illness 
was 16.4 ± 13.5 years. The average antipsychotic dosage 
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(± standard deviation (SD)) at assessment was 
717 ± 770.3 CPZ mg equivalents per day. The 168 Dutch 
patients were older (48.8 ± 12.4 years) and were admitted 
to the hospital for an average of 23.4 ± 12.9 years. In addi-
tion, this group was less homogenous with respect to dis-
ease characteristics and included, according to the 
Diagnostic and Statistical Manual of Mental Disorders 4th 
Edition (DSM-IV) Axis I, patients with schizophrenia 
(N = 112), psychosis (N = 9), affective disorders (N = 27), 
another Axis I diagnosis (N = 11), and no Axis I diagnosis 
(N = 9).
The associations between SNPs and orofacial TD (TDof) 
are shown in Table 1 for the Dutch and Siberian patient pop-
ulations. Significant associations were found between eight 
SNPs encoding four receptors (GRIN2B, GRIN2A, DRD3, 
and HTR2C) and TDof. However, these SNPs were not the 
same for the two groups. The associations between SNPs and 
limb-truncal TD (TDlt) are displayed in Table 2 for the Dutch 
and Siberian patients. Significant associations were found 
between nine SNPs of two receptors (GRIN2A and DRD3) 
and TDlt. Yet, only rs1345423 in GRIN2A was significantly 
associated with TDlt in both patient groups: Dutch patients 
(B = −0.18, P = 0.0190) and Siberian patients (TD expression 
level, sum of scores for five to seven signs: P = 0.02504). The 
associations between SNPs and overall TD are displayed in 
Table 3 for the Dutch and Siberian patient populations. 
Significant associations were found in seven specific SNPs 
encoding three receptors (GRIN2B, GRIN2A, and DRD3). 
Only rs1345423 in GRIN2A was significantly associated 
with overall TD in both studied groups.
Table 1. Associations between specific SNPs and orofacial TD in the Dutch and Siberian schizophrenic populations.
Receptor SNP Dutch population Siberian schizophrenic population
 TDof (B, P value) TDof (OR (95% CI), P value) TD expression level: sum of 
scores for 1–4 signs (P valuea)
GRIN2B rs220599 X X P = 0.04451
GRIN2A rs7192557 B = 0.22, P = 0.0291 X X
 rs1650420 B = 0.16, P = 0.0336 X X
 rs11646587 X OR = 0.62 (0.38–1.00), P = 0.04652 X
 rs7206256 X OR = 1.73 (1.02–2.91), P = 0.03570 X
 rs1345423 X OR = 0.35 (0.14–0.86), P = 0.01043 P = 0.027865
DRD3 rs167770 X P = 0.01751 X
HTR2C rs4911871 B = −0.18, 
P = 0.0131
X X
TDof: orofacial tardive dyskinesia; OR: odds ratio; 95% CI: 95% confidence interval.
B = regression coefficient, P = chance, sum of scores = scores of AIMS scale.
aOriginal value + 1, followed by log2-transformation.
Table 2. Associations between specific SNPs and TDlt in the Dutch and Siberian schizophrenic populations.
Receptor SNP Dutch population Siberian schizophrenic population
 TDlt (B, P value) TDlt (OR (95% CI), P value) TD expression level:
sum of scores for 5–7 
signs (P valuea)
GRIN2A rs1345423 B = −0.18, 
P = 0.0190
X P = 0.02504
 rs7192557 B = 0.22, P = 0.0430 X X
 rs1650420 B = 0.16, P = 0.0471 X X
 rs11866328 B = 0.16, P = 0.0330 X X
 rs7190619 X OR = 0.44[0.19–1.03], P = 0.04292 P = 0.02510
 rs9788936 X OR = 0.51[0.27–1.00], P = 0.04020 X
 rs11644461 X X P = 0.03875
DRD3 rs963468 X X P = 0.01533
 rs167770 X X P = 0.012236
TDlt: limb-truncal tardive dyskinesia; OR = odds ratio; 95% CI = 95% confidence interval.
Bold italics are statistically significant in both populations.
B = regression coefficient, P = chance, sum of scores = scores of AIMS scale.
aOriginal value + 1, followed by log2-transformation.
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Discussion
The results were inconsistent between the two populations, 
except for rs1345423 in GRIN2A for limb-truncal and all 
types of TD. The following methodological problems may 
explain these differences: the limited sample size (particu-
larly of the Dutch study already published in PLoS One), 
multiple testing of several SNPs, age differences between 
the patient groups, diagnostic heterogeneity, variable influ-
ence of other risk factors, and poor clinical diagnosis of TD 
with the use of the AIMS.1,18 Furthermore, our study was 
cross-sectional, while the Dutch study was prospective with 
two follow-ups. This may have resulted in different out-
comes, considering that dyskinesia fluctuates over time in 
relation to stress, anxiety, or fatigue.1 However, in our opin-
ion, the main problem was that the magnitude of the associa-
tion between the presence of a specific genetic receptor 
variant and the clinical phenomenon of TD was at the utmost 
very small and therefore irrelevant.
Glutamatergic receptors
In our current study, only rs1345423 in GRIN2A showed a sig-
nificant association with TD in the Dutch and Siberian patient 
populations. This [G/T]-SNP is an intron variant in GRIN2A, 
encoding one of the glutamatergic N-methyl-d-aspartate 
(NMDA) receptor subunits. It is a tag SNP, which is genetically 
independent from the GRIN2A variants rs7192557 (rs1969060) 
and rs8057394 that are associated with dyskinesia’s age of 
onset in Huntington’s disease, as well as with levodopa-induced 
dyskinesia.15 The OR for rs1345423 was smaller (0.42; 95% 
CI: 0.20–0.89, P = 0.0152) for “all locations” TD than for 
rs7192557 and levodopa-induced dyskinesia in 101 patients 
with Parkinson’s disease (OR = 3.21; 95% CI: 1.37–7.51, 
P = 0.0062). The association was not found in the Siberian pop-
ulation when another statistical method was used.15 Therefore, 
this finding is not likely of significant clinical importance.
Dopaminergic receptors
The magnitude of the association between the presence of vari-
ants of the DA receptor and the presence of TD is very small. In 
a meta-analysis of 12 studies, Bakker et al.21 found a pooled OR 
(1.17, 95% CI: 1.01–1.37) for TD among carriers of the Ser9Gly 
allele (rs6280) in the DRD3 gene that was smaller than the OR 
found by Lerer et al.22 (OR = 1.33, 95% CI: 1.04–1.70) in a 
meta-analysis of eight studies. Tsai et al.23 found a non-signifi-
cant OR after meta-analyzing 13 studies. Comparable results 
were found for DRD2 24,25 and DRD4.26–30 The magnitude of the 
association between DRD polymorphisms and TD is too weak 
to have a pathophysiological meaning.
A pharmacological problem should also be discussed. 
The Ser9Gly DRD3 variant (rs6280) has functional conse-
quences.31 The Gly variant has a frequency of ~35% in non-
African populations, and is actually the ancestral allele. The 
homogenous Gly variant has been associated with 4-fold 
greater DA binding affinity in vitro.32 However, the affinity 
of DA for its D2-family receptors is in the micromolar range; 
while, the affinity of antipsychotic drugs (when clozapine 
and quetiapine are excluded) is in the nanomolar range.33 
Even when DA would have sufficient affinity to compete 
with antipsychotics for binding to the homogenous Ser9Gly 
variant of DRD3,32 it is difficult to understand how this acti-
vation could overcome the remaining blockade of DRD2 and 
DRD4 receptors within the dorsal striatum. The DRD3 recep-
tor is characterized by an extraordinary large binding affinity 
for DA.34 It should be emphasized that DRD3 receptors are 
largely confined to the ventral striatum;34 while, the site of 
action of TD inducing mechanisms should be the putamen.2
It can be concluded that DA is unlikely to compete with 
antipsychotics for the DA type 2 receptor, even when it has far 
greater affinity than normal to a genetic variant of DRD2, 
DRD3, or DRD4. Moreover, most antipsychotics are full antag-
onists and dysfunctional variants of DRD2, DRD3, or DRD4 do 
not modify the influence of these drugs. This probably explains 
Table 3. Associations between specific SNPs and either type of TD in the Dutch and Siberian schizophrenic populations.
Receptor SNP Dutch population Siberian schizophrenic population
 TD (B, P value) TD (OR (95% CI), P value) TD expression level:
sum of scores for 1–7 
signs (P valuea)
GRIN2B rs2192970 X OR = 1.93 (1.22–3.06), P = 0.005411 X
GRIN2A rs1345423 B = −0.13, P = 0.0421 OR = 0.42 (0.20–0.89), P = 0.015210 P = 0.014524
 rs7192557 B = 0.22, P = 0.0159 X X
 rs1650420 B = 0.16, P = 0.0193 X X
 rs11644461 B = −0.13, P = 0.0385 X X
DRD3 rs324035 X X P = 0.03211
 rs167770 X X P = 0.02197
OR: odds ratio; 95% CI: 95% confidence interval.
Bold italics are statistically significant in both populations.
B = regression coefficient, P = chance, sum of scores = scores of AIMS scale.
aOriginal value + 1, followed by log2-transformation.
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why genetic variants of DRD2, DRD3, or DRD4 have very little 
influence on the prevalence of TD in patients treated with antip-
sychotic drugs. Any possible influence of the genetically deter-
mined receptor inactivity on the vulnerability of TD should 
have taken place before treatment with DA antagonists was 
started. Moreover, atypical antipsychotics would be expected to 
increase dyskinesia instead of having protective activity, as 
atypical antipsychotics are known to facilitate DA release.12 
Any extra DA would likely augment dyskinesia by activating 
excitatory DRD1, expressed by medium spiny neurons (MSNs) 
of the direct extrapyramidal pathway (Figure 1), which is far 
less potently antagonized by antipsychotic drugs. Moreover, 
release of extra DA would increase oxidative stress within indi-
rect pathway MSNs, augmenting neurotoxicity.
Serotonergic receptors
The results are also conflicting with respect to HTR2A and 
HTR2C. Several studies have shown an association, for exam-
ple, between T102C variants of the HTR2A gene and Cys23Ser 
variants of HTR2C and the development of TD; while, other 
reports are negative.35 The affinity of serotonin itself for these 
binding sites is low,36,37 compared with the binding affinity of 
“atypical” antipsychotic drugs.12 However, these receptors 
spontaneously signal for cellular effector mechanisms in the 
absence of ligands, and HTR2C may have higher constitutive 
activity than HTR2A.38 In this situation, a ligand binding to the 
receptor may also act as an inverse agonist, that is, changing 
the activity of the receptor in the opposite direction instead of 
increasing or blocking it. This occurred when this receptor 
was bound by atypical antipsychotics.12,38 In these cases, the 
variant (of HTR2A or HTR2C) with increased constitutive 
activity would have greater benefit and the variant with 
decreased or absent constitutive activity would have less ben-
efit due to the complete blockade of these receptors by atypi-
cal antipsychotic drugs. Thus, the affinity of previous and 
currently used antipsychotics for the HTR2A and HTR2C 
receptors should be considered when analyzing the influence 
of polymorphisms on the severity of dyskinesia. The differ-
ence between active and inactive receptor variants will be 
greater for classical antipsychotics with low binding potential 
for HTR2 receptors. This may explain the inconsistencies 
observed in studies evaluating the association between TD 
and genetic variations of HTR2C. The most frequently inves-
tigated 5-HT2C polymorphism, Cys23Ser (rs6318), was asso-
ciated with an increased risk of TD and Parkinsonism,39–44 but 
the results from different studies varied. The HTR2C gene is 
found on the long arm of the X-chromosome (Xq24). 
Therefore, males are hemizygotes, and always homozygous. 
Al Hadithy et al. demonstrated that there was a significant 
association between carriers of the 23Ser allele of HTR2C and 
parkinsonian bradykinesia in males, but not females.40 Wilffert 
et al.44 did not find a correlation between TD and 23Ser male 
carriers when analyzed separately. However, orofacial and 
TDlt scores were statistically significantly higher in male 
patients carrying combinations of the 9Ser variant of the 
DRD3 gene and 23Ser allele of HTR2C.44 This may corre-
spond with the findings of Segman et al.,39 who found no asso-
ciation with 23Ser male carriers, but the highest orofacial 
dyskinesia scores were in combined carriers of 9Gly DRD3 
and 23Ser HTR2C (not specified for males and females). Al 
Hadithy et al.42 showed that Ser9Gly and Cys23Ser polymor-
phisms affect the phenotypic variability of TDlt after its occur-
rence, but not of TDof. Gunes et al.41 studied only male 
subjects with several types of extrapyramidal symptoms 
(Parkinsonism, dystonia, and/or dyskinesia) and observed a 
strong association with 23Ser HTR2C carriers. It should be 
emphasized that the drug treatments probably differed between 
studies. Gunes et al.41 excluded all patients who were using 
atypical drugs, while the other authors included patients who 
were on atypical antipsychotics.39,40,42–44 Unfortunately, 
Segman et al.45 did not specify the antipsychotics used by their 
population of Jewish patients recruited from several centers in 
Israel. Atypical antipsychotics are assumed to cause less 
Parkinsonism and TD by blocking HTR2A/2C.11,46–48 
Figure 1. The indirect and direct extrapyramidal pathways.
ENK: enkephalin; GPe: globus pallidus, external segment; GPi: globus palli-
dus, internal segment; SNc: substantia nigra, pars compacta; SNr: substantia 
nigra, pars reticulata; SP/DYN = substance P/dynorphin; STh: subthalamic 
nucleus; D1, D2: medium sized spiny neurons with D1 or D2 receptors.
Red: excitatory and blue: inhibitory (colour figure in  
DOI: 10.1177/2050312116643673)
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Therefore, the differences between the results of these studies 
may be partly explained by the use of HTR2A/2C blocking 
agents, which apparently decrease the differences between 
carriers and non-carriers. This also supports our idea that the 
inactive variant of HTR2C protects against developing TD.
To understand how blockade of 5-HT2A/2C receptors 
results in less Parkinsonism and TD, the neuronal localiza-
tion of these receptors should be considered (Figure 2).49 The 
5-HT2A/2C receptors not only activate GABAergic interneu-
rons within the midbrain, striatum, and prefrontal cortex, but 
also stimulate MSNs within the striatum.49 Blockade in the 
midbrain results in DA release, but blocking the striatum 
directly inhibit MSNs.49 This inhibition may protect these 
MSNs from neurotoxicity induced by oxidative stress caused 
by oxidative metabolism of the excess DA.2
Conclusion
Only rs1345423 in GRIN2A showed a significant association 
with TD in the Dutch and Siberian patient populations. It 
may be concluded that a direct modulation of the DA type 2 
receptors is unlikely to be responsible for the protective 
effects of atypical antipsychotic drugs on TD. The 5-HTR2C 
receptor may better explain this effect, particularly when its 
constitutive activity is considered.
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Figure 2. Model for the distribution of 5-HT2A and 5-HT2C receptors in the midbrain, striatum, and prefrontal cortex.
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striatal neuron; and tan: striatal cholinergic interneuron. The model explains the clinical differences when 5-HT2C receptors show far more constitutive 
activity than 5-HT2A receptors (colour figure in DOI: 10.1177/2050312116643673).
8 SAGE Open Medicine
Informed consent
Written informed consent was obtained from all subjects before the 
study. None of the participants had a compromised capacity/ability 
to consent; hence, consent obtained from the next of kin was not 
necessary and not recommended by the Local Ethics Committee.
References
 1. Loonen AJ and Van Praag HM. Measuring movement dis-
orders in antipsychotic drug trials: the need to define a new 
standard. J Clin Psychopharmacol 2007; 27: 423–430.
 2. Loonen AJ and Ivanova SA. New insights into the mechanism 
of drug-induced dyskinesia. CNS Spectr 2013; 18: 15–20.
 3. Tenback DE and Van Harten PN. Epidemiology and risk factors 
for (tardive) dyskinesia. Int Rev Neurobiol 2011; 98: 211–230.
 4. Howes OD and Kapur S. The dopamine hypothesis of schizo-
phrenia: version III–the final common pathway. Schizophr 
Bull 2009; 35: 549–562.
 5. Lau CI, Wang HC, Hsu JL, et al. Does the dopamine hypoth-
esis explain schizophrenia? Rev Neurosci 2013; 4: 389–400.
 6. Boyd KN and Mailman RB. Dopamine receptor signaling and 
current and future antipsychotic drugs. In: Gross G and Geyer 
MA (eds) Current antipsychotics (Handbook of experimental 
pharmacology). Berlin, Heidelberg: Springer-Verlag, 2012, 
pp. 53–86.
 7. Korczyn AD. Pathophysiology of drug-induced dyskinesias. 
Neuropharmacology 1972; 11: 601–607.
 8. Aquino CC and Lang AE. Tardive dyskinesia syndromes: cur-
rent concepts. Parkinsonism Relat Disord 2014; 20(Suppl. 1): 
S113–S117.
 9. Casey DE. Pathophysiology of antipsychotic drug-induced 
movement disorders. J Clin Psychiatry 2004; 65(Suppl. 9): 
25–28.
 10. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dys-
kinesia in the era of typical and atypical antipsychotics. Part 2: 
incidence and management strategies in patients with schizo-
phrenia. Can J Psychiatry 2005; 50: 703–714.
 11. Leysen JE. 5-HT2 receptors. Curr Drug Targets CNS Neurol 
Disord 2004; 3: 11–26.
 12. Meltzer HY. Serotonergic mechanisms as targets for exist-
ing and novel antipsychotics. In: Gross G and Geyer MA 
(eds) Current antipsychotics (Handbook of experimental 
pharmacology). Berlin, Heidelberg: Springer-Verlag, 2012, 
pp. 87–124.
 13. Wilffert B, Zaal R and Brouwers JR. Pharmacogenetics as a 
tool in the therapy of schizophrenia. Pharm World Sci 2005; 
27: 20–30.
 14. Koning JP, Tenback DE, Van Os J, et al. Dyskinesia and par-
kinsonism in antipsychotic-naive patients with schizophrenia, 
first-degree relatives and healthy controls: a meta-analysis. 
Schizophr Bull 2010; 36: 723–731.
 15. Ivanova SA, Loonen AJ, Pechlivanoglou P, et al. NMDA 
receptor genotypes associated with the vulnerability to develop 
dyskinesia. Transl Psychiatr 2012; 2: e67.
 16. Bakker PR, Al Hadithy AF, Amin N, et al. Antipsychotic-
induced movement disorders in long-stay psychiatric patients 
and 45 tag SNPs in 7 candidate genes: a prospective study. 
PLoS One 2012; 7: e50970.
 17. Andreasen NC, Pressler M, Nopoulos P, et al. Antipsychotic 
dose equivalents and dose-years: a standardized method for 
comparing exposure to different drugs. Biol Psychiatry 2010; 
67: 255–262.
 18. Loonen AJ and Hovens JE. Movement disorders in clinical 
research. Tijdschr Psychiatr 2006; 48: 647–650.
 19. Schooler NR and Kane JM. Research diagnoses for tardive 
dyskinesia. Arch Gen Psychiatry 1982; 39: 486–487.
 20. Gonzalez JR, Armengol L, Sole X, et al. SNPassoc: an 
R package to perform whole genome association studies. 
Bioinformatics 2007; 23: 644–645.
 21. Bakker PR, van Harten PN and van Os J. Antipsychotic-
induced tardive dyskinesia and the Ser9Gly polymorphism 
in the DRD3 gene: a meta analysis. Schizophr Res 2006; 83: 
185–192.
 22. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of 
tardive dyskinesia: combined analysis of 780 patients supports 
association with dopamine D3 receptor gene Ser9Gly poly-
morphism. Neuropsychopharmacology 2002; 27: 105–119.
 23. Tsai HT, North KE, West SL, et al. The DRD3 rs6280 poly-
morphism and prevalence of tardive dyskinesia: a meta-anal-
ysis. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 
57–66.
 24. Zai CC, Hwang RW, De Luca V, et al. Association study of 
tardive dyskinesia and twelve DRD2 polymorphisms in schiz-
ophrenia patients. Int J Neuropsychopharmacol 2007; 10: 
639–651.
 25. Bakker PR, van Harten PN and van Os J. Antipsychotic-
induced tardive dyskinesia and polymorphic variations in 
COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis 
of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 
544–556.
 26. Segman RH, Goltser T, Heresco-Levy U, et al. Association of 
dopaminergic and serotonergic genes with tardive dyskinesia 
in patients with chronic schizophrenia. Pharmacogenomics J 
2003; 3: 277–283.
 27. Lattuada E, Cavallaro R, Serretti A, et al. Tardive dyskine-
sia and DRD2, DRD3, DRD4, 5-HT2A variants in schizo-
phrenia: an association study with repeated assessment. Int J 
Neuropsychopharmacol 2004; 7: 489–493.
 28. Srivastava V, Varma PG, Prasad S, et al. Genetic suscepti-
bility to tardive dyskinesia among schizophrenia subjects: 
IV. Role of dopaminergic pathway gene polymorphisms. 
Pharmacogenet Genomics 2006; 16: 111–117.
 29. Lee HJ, Kang SG, Choi JE, et al. No association between 
dopamine D4 receptor gene -521 C/T polymorphism and tar-
dive dyskinesia in schizophrenia. Neuropsychobiology 2007; 
55: 47–51.
 30. Zai CC, Tiwari AK, Basile V, et al. Association study of tar-
dive dyskinesia and five DRD4 polymorphisms in schizophre-
nia patients. Pharmacogenomics J 2009; 9: 168–174.
 31. Lencz T. Pharmacogenetics of antipsychotic-induced side 
effects. Dialogues Clin Neurosci 2009; 11: 405–415.
 32. Lundstrom K and Turpin MP. Proposed schizophrenia-related 
gene polymorphism: expression of the Ser9Gly mutant human 
dopamine D3 receptor with the Semliki forest virus system. 
Biochem Biophys Res Commun 1996; 225: 1068–1072.
 33. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980; 
32: 229–313.
 34. Schwartz JC, Levesque D, Martres MP, et al. Dopamine D3 
receptor: basic and clinical aspects. Clin Neuropharmacol 
1993; 16: 295–314.
Ivanova et al. 9
 35. Arranz MJ, Rivera M and Munro JC. Pharmacogenetics of 
response to antipsychotics in patients with schizophrenia. CNS 
Drugs 2011; 25: 933–969.
 36. Farrow JT and Van Vunakis H. Characteristics of D-lysergic 
acid diethylamide binding to subcellular fractions derived 
from rat brain. Biochem Pharmacol 1973; 22: 1103–1113.
 37. Leysen JE, Gommeren W and Laduron PM. Spiperone: a 
ligand of choice for neuroleptic receptors. 1. Kinetics and 
characteristics of in vitro binding. Biochem Pharmacol 1978; 
27: 307–316.
 38. Aloyo VJ, Berg KA, Spampinato U, et al. Current status 
of inverse agonism at serotonin 2A (5-HT2A) and 5-HT2C 
receptors. Pharmacol Ther 2009; 121: 160–173.
 39. Segman RH, Heresco-Levy U, Finkel B, et al. Association 
between the serotonin 2C receptor gene and tardive dyskinesia 
in chronic schizophrenia: additive contribution of 5-HT2Cser 
and DRD3gly alleles to susceptibility. Psychopharmacology 
2000; 152: 408–413.
 40. Al Hadithy AF, Wilffert B, Stewart RE, et al. Pharmacogenetics 
of parkinsonism, rigidity, rest tremor, and bradykinesia in 
African-Caribbean inpatients: differences in association 
with dopamine and serotonin receptors. Am J Med Genet B 
Neuropsychiatr Genet 2008; 147: 890–897.
 41. Gunes A, Dahl ML, Spina E, et al. Further evidence for the 
association between 5-HT2C receptor gene polymorphisms 
and extrapyramidal side effects in male schizophrenic patients. 
Eur J Clin Pharmacol 2008; 64: 477–482.
 42. Al Hadithy AF, Ivanova SA, Pechlivanoglou P, et al. 
Tardive dyskinesia and DRD3, HTR2A and HTR2C gene 
polymorphisms in Russian psychiatric inpatients from Siberia. 
Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 
475–481.
 43. Al Hadithy AF, Wilffert B, Bruggeman R, et al. Lack of 
association between antipsychotic-induced Parkinsonism or 
its subsymptoms and rs4606 SNP of RGS2 gene in African-
Caribbeans and the possible role of the medication: the Curacao 
extrapyramidal syndromes study X. Hum Psychopharmacol 
2009; 24: 123–128.
 44. Wilffert B, Al Hadithy AF, Sing VJ, et al. The role of dopamine 
D3, 5-HT2A and 5-HT2C receptor variants as pharmacoge-
netic determinants in tardive dyskinesia in African-Caribbean 
patients under chronic antipsychotic treatment: curacao 
extrapyramidal syndromes study IX. J Psychopharmacol 
2009; 23: 652–659.
 45. Segman R, Neeman T, Heresco-Levy U, et al. Genotypic 
association between the dopamine D3 receptor and tardive 
dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4: 
247–253.
 46. Duinkerke SJ, Botter PA, Jansen AA, et al. Ritanserin, a 
selective 5-HT2/1C antagonist, and negative symptoms in 
schizophrenia. A placebo-controlled double-blind trial. Brit J 
Psychiatry 1993; 163: 451–455.
 47. Grant S and Fitton A. Risperidone. A review of its pharmacol-
ogy and therapeutic potential in the treatment of schizophre-
nia. Drugs 1994; 48: 253–273.
 48. Owens DG. Extrapyramidal side effects and tolerability of 
risperidone: a review. J Clin Psychiatry 1994; 55(Suppl.): 
29–35.
 49. Loonen AJM and Ivanova SA. Role of 5-HT2C receptors in 
dyskinesia. Int J Pharm Pharm Sci 2016; 8: 5–10.
